

Twenty Years of Active Bacterial Core Surveillance

Technical Appendix

Technical Appendix Table. Key uses and findings of Active Bacterial Core surveillance data for vaccine development, evaluation, and policy formulation*

| Pathogen | Vaccines | Key uses and findings |
|--|---|--|
| <i>Streptococcus pneumoniae</i> | PCV7 and PCV13 | Selection of serotypes included in PCV7 and PCV13 Informed ACIP recommendations for children <5 y of age (1,2) Tracking postlicensure declines in cases (3) Documented effectiveness of PCV7 (4) Monitoring incidence of non-vaccine serotypes (5) Accelerated regulatory approval of PCV13 (6) Informed ACIP recommendations for PCV13 use in immunocompromised adults and children (7,8) |
| <i>Neisseria meningitidis</i> | Conjugate vaccines Serogroup B vaccines | Informed ACIP recommendations for children 11–18 y of age (9–11) Informed ACIP recommendations for booster dose (12) Documented vaccine effectiveness (13) Informed ACIP infant meningococcal recommendations (14) Evaluated potential effect on serogroup B disease in United States (15) |
| <i>Haemophilus influenzae</i> | Hib vaccine | Tracking postlicensure declines in Hib disease (16) Tracking shift toward non-Hib disease (16) Evaluated effect of vaccine shortages (17–19) |
| Group A <i>Streptococcus</i> | M-type vaccine (under development) | Estimated degrees of protection against severe group A streptococcal infections (20,21) |
| Group B <i>Streptococcus</i> | Trivalent vaccine (under development) | Informing development of vaccine to prevent early-onset (within 1 week of life) group B streptococcal disease (22) |
| Methicillin –resistant <i>Staphylococcus aureus</i> | <i>S. aureus</i> vaccine (under development) | Determining population groups to target (23) |

*ACIP, Advisory Committee on Immunization Practices; Hib, *H. influenzae* type b vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.

References

- Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. MMWR Recomm Rep. 2000;49(RR09):1–35. [PubMed](#)
- Nuorti JP, Whitney CG; Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1–18. [PubMed](#)
- Pilishvili T, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41. [PubMed](#)
- Whitney CG, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495–502. [PubMed](#)

5. Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? *Clin Infect Dis*. 2008;46:183–5. [10.1086/524661](https://doi.org/10.1086/524661). [PubMed](#)
6. FDA. Vaccines, Blood and Biologics: Prevnar 13. 2013 [cited 2013 November 4]. <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm>.
7. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. 2012;61:816–9. [PubMed](#)
8. CDC. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. 2013;62:521–4. [PubMed](#)
9. CDC. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11–18 Years with Meningococcal Conjugate Vaccine. *MMWR Morb Mortal Wkly Rep*. 2007;56:794–5. [PubMed](#)
10. Harrison LH, et al. Risk of meningococcal infection in college students. *JAMA*. 1999;281:1906–10. [PubMed](#)
11. Harrison LH, et al. Invasive meningococcal disease in adolescents and young adults. *JAMA*. 2001;286:694–9. [PubMed](#)
12. CDC. Updated recommendations for use of meningococcal conjugate vaccines—Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Morb Mortal Wkly Rep*. 2011;60:72–6. [PubMed](#)
13. Macneil JR, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. *Pediatr Infect Dis J*. 2011;30:451–5. [PubMed](#)
14. CDC. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. *MMWR Morb Mortal Wkly Rep*. 2013;62:52–4. [PubMed](#)
15. Cohn AC, et al. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. *Clin Infect Dis*. 2010;50:184–91. [PubMed](#)
16. MacNeil JR, et al. Current epidemiology and trends in invasive *Haemophilus influenzae* disease—United States, 1989–2008. *Clin Infect Dis*. 2011;53:1230–6. [PubMed](#)

17. Briere EC, et al. *Haemophilus influenzae* type b disease and vaccine booster dose deferral, United States, 1998–2009. *Pediatrics*. 2012;130:414–20. Epub 2012 Aug 6. [PubMed](#)
<http://dx.doi.org/10.1542/peds.2012-0266>
18. CDC. Continued shortage of *Haemophilus influenzae* Type B (Hib) conjugate vaccines and potential implications for Hib surveillance—United States 2008. *MMWR Morb Mortal Wkly Rep*. 2008;57:1252–5. [PubMed](#)
19. Jackson ML, et al. Modeling insights into *Haemophilus influenzae* type b disease, transmission, and vaccine programs. *Emerg Infect Dis*. 2012;18:13–20. [PubMed](#)
<http://dx.doi.org/10.3201/eid1801.110336>
20. McNeil SA, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. *Clin Infect Dis*. 2005;41:1114–22. Epub 2005 Sep 12. [PubMed](#)
21. O’Loughlin RE, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000–2004. *Clin Infect Dis*. 2007;45:853–62. [PubMed](#)
22. Madhi SA, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. *Vaccine*. 2013;31(Suppl 4):D52–7. [PubMed](#)
<http://dx.doi.org/10.1016/j.vaccine.2013.02.029>
23. Lucero CA, et al. Evaluating the potential public health impact of a *Staphylococcus aureus* vaccine through use of population-based surveillance for invasive methicillin-resistant *S. aureus* disease in the United States. *Vaccine*. 2009;27:5061–8. [PubMed](#)